Non-invasive diagnostics of Hemolens awarded in the Polish Product of the Future competition

Wrocław, April 21, 2023. – Wrocław-based Hemolens Diagnostics has been recognized in this year’s Polish Product of the Future competition for its innovative coronary artery disease diagnostics solutions. 

Hemolens Diagnostics is a MedTech company specializing in developing and delivering unique technology for personalized, non-invasive, and accurate diagnostics to reduce invasive procedures in healthcare. Its latest product, the Cardiolens FFR-CT Pro non-invasive diagnostic test, has been recognized by the jury of the Polish Product of the Future competition for the unique technological solution that enables accurate and precise diagnostics on an outpatient basis. 

“This award is a great reward for us and is a confirmation that our solution has great potential and usage in the diagnostics of chronic coronary artery disease in Poland and around the world. We believe in innovative medicine that, thanks to technology, evolves from invasive procedures to more precise, safe, and patient-friendly methods of diagnostics and treatment.” – said Wojciech Jeżewski, CEO of Hemolens Diagnostics. “We are proud to collaborate with Polish and foreign medical facilities in the development of a diagnostic tool that will allow, in the future, to reduce examination time and provide a precise and accurate diagnosis of coronary artery disease without the need for invasive procedures. The implementation of the Cardiolens FFR-CT Pro diagnostic method will be a breakthrough for medical facilities in Poland and around the world, as it can allow cardiologists to make more accurate diagnoses and prepare personalized treatment plans for their patients.” 

With this new non-invasive technology, cardiologists will be able to obtain accurate and precise information about the condition of the coronary arteries without any of complications or discomfort caused by invasive procedures for the patient. 

This will also be a huge asset for medical facilities, as Cardiolens FFR-CT Pro diagnostics can also contribute to more efficient resource management in the facility. The non-invasive nature of our method also has the potential to change the diagnostic pathway for coronary artery disease from requiring a hospital stay to an outpatient pathway. 

With accurate and precise diagnostics, medical facilities will be able to direct their resources to the patients who need them most, saving time and money. In turn, patients with suspected stable coronary artery disease will be able to have access to Cardiolens FFR-CT Pro’s more comfortable and complication-free diagnostic procedure and receive a diagnosis and treatment plan more quickly and conveniently, making way for patients requiring urgent care. 

As the CEO of Hemolens Diagnostics adds, “This is also a move towards Value-Based Health Care, as earlier prevention and scalable diagnostics can potentially improve patient outcomes. Furthermore, patients are more likely to follow treatment plans when they can receive test results in a more user-friendly, visual format.” 

The ‘Polish Product of the Future’ competition is a prestigious event that awards the most innovative products of the Polish industry every year. Hemolens Diagnostics is the next company that was honored in this prestigious category. 

The Cardiolens FFR-CT Pro diagnostic method has the status of a certified medical device, and the efforts of the development team have additionally been honored with the granting of patents by the European and Japanese Patent Office. The product was also recently awarded at the XXVI Congress of the Polish Society of Cardiology and recognized in the Start-Up-Med and Huawei Startup Challenge competitions, thanks to its commitment to the development of cardiovascular medicine and diagnostics.

This is a medical device. Use it in accordance with the instructions. 

Intended Use:  

Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement.  The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.